Cradle Bio vs Pliant Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pliant Therapeutics leads in AI visibility (62 vs 20)
Cradle Bio logo

Cradle Bio

EmergingBiotechnology

AI Protein Engineering

Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial and therapeutic use.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
24
Perplexity
17
Gemini
15

About

Cradle Bio is an AI protein engineering company founded in 2021 in Amsterdam, having raised $73M to build an AI-powered protein design platform. The platform combines generative AI with wet-lab experimentation to accelerate the iterative process of engineering proteins with improved stability, activity, and manufacturability. Cradle's technology enables researchers to design thousands of protein variants computationally and prioritize those most likely to succeed in laboratory validation, compressing protein engineering timelines from years to months. The company serves both industrial biotechnology customers engineering enzymes for biomanufacturing and pharmaceutical companies developing next-generation antibody therapeutics. Cradle partners with contract research organizations and biopharmaceutical companies to integrate AI-assisted protein design into existing discovery workflows. The company has been recognized as a leader in the European deep tech ecosystem and positions protein engineering AI as enabling a new era of designed biologics for medicine and sustainable manufacturing.

Full profile
Pliant Therapeutics logo

Pliant Therapeutics

ChallengerBioTech

Fibrotic Disease

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

AI VisibilityBeta
Overall Score
B62
Category Rank
#1 of 1
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
54
Perplexity
60
Gemini
55

About

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Full profile

AI Visibility Head-to-Head

20
Overall Score
62
#1
Category Rank
#1
64
AI Consensus
62
up
Trend
up
24
ChatGPT
54
17
Perplexity
60
15
Gemini
55
30
Claude
64
21
Grok
69

Key Details

Category
AI Protein Engineering
Fibrotic Disease
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Cradle Bio
AI Protein Engineering
Only Pliant Therapeutics
Fibrotic Disease

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.